EVO vs PHAT
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
EVO shows bearish fundamentals based on deterministic rules. Financial strength is strong (F-Score 6/9). Concerns include weak profitability or high valuation.
PHAT presents a classic high-growth biotechnology profile, anchored by a stable Piotroski F-Score of 4/9 and an impressive 94.10% YoY revenue growth. While the company currently operates with deeply negative profit margins (-126.35%) and negative book value, the Forward P/E of 8.17 is exceptionally attractive compared to the healthcare sector average of 88.62. Strong analyst conviction with a target price of $23.70 and a consistent track record of earnings beats suggest a rapid transition toward profitability. The primary headwinds are technical bearishness and negative insider sentiment, which contrast with the strong fundamental growth trajectory.
Compare Another Pair
Related Comparisons
EVO vs PHAT: Head-to-Head Comparison
This page compares Evotec SE (EVO) and Phathom Pharmaceuticals, Inc. (PHAT) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.